Novel and emerging therapies for asthma.
At present, there are a wide variety of novel and emerging therapeutic approaches for the treatment of asthma. Here, we will summarize these state-of-the-art approaches, including specific and nonspecific mediator inhibition-- a quest that has been on going for more than 25 years-- together with cytokine modulation in asthma (primarily attempting to modulate the Th2-Th1 balance in asthma), targeting cell recruitment, angiogenesis, signal transduction and gene transduction pathways. Finally, we will discuss the recently approved anti-IgE therapy for the treatment of allergic asthma and immune modulation using CpG oligodeoxynucleotides.
Leath
Thomas M
TM
Department of Medicine, Section on Pulmonary, Critical Care, Allergy & Immunological Diseases, Center for Human Genomics, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Singla
Manav
M
Peters
Stephen P
SP
D000818:Animals; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000188:drug therapy*; D018899:CpG Islands; D016207:Cytokines / Q000276:immunology; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology; D020024:Leukotriene Antagonists / Q000627:therapeutic use; D018919:Neovascularization, Physiologic / Q000187:drug effects; D009838:Oligodeoxyribonucleotides / Q000627:therapeutic use; D000069444:Omalizumab; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects
D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D016207:Cytokines; D020024:Leukotriene Antagonists; D009838:Oligodeoxyribonucleotides; D010726:Phosphodiesterase Inhibitors; D000069444:Omalizumab; D007073:Immunoglobulin E